Actively Recruiting
Phase 4 Study of Methotrexate to Improve Palynziq Treatment in Adults With Phenylketonuria PKU
Led by BioMarin Pharmaceutical · Updated on 2026-06-17
12
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of methotrexate MTX alongside Palynziq to reduce immune responses and improve how well Palynziq works in adults with phenylketonuria PKU. This Phase 4 study includes adults with PKU who either have not used Palynziq before or have used it but still have high blood phenylalanine levels. The goal is to see if combining MTX with Palynziq can make the treatment more tolerable and effective. Participants are divided into two groups those new to Palynziq Cohort A and those who have been on Palynziq for at least 24 weeks but still have high blood phenylalanine Cohort B. Both groups take oral MTX once a week at 15 mg. Cohort A starts with a 4-week screening, then a 4-week MTX-only period to check tolerability, followed by 24 weeks of combined MTX and Palynziq treatment. Cohort B has a 4-week screening, then 24 weeks of combined treatment with MTX and Palynziq, including a 4-week MTX tolerability check. After 24 weeks, MTX is stopped, and Palynziq alone continues for an additional 24 weeks. During the study, participants are regularly monitored for safety and how well they tolerate MTX. Researchers measure blood phenylalanine levels and immune responses to Palynziq at various points, including baseline, Week 5, Week 9, Week 25, and Week 49. Other assessments include tracking side effects and Palynziq levels in the blood. The total study duration for participants is up to 49 weeks, including screening, treatment, and follow-up periods.
CONDITIONS
Brief Title
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
Research Team
T
Trial Specialist
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here